^
Association details:
| Biomarker: | PGR overexpression |
|---|---|
| Cancer: | HER2 Positive Breast Cancer |
| Drug: | Kadcyla (ado-trastuzumab emtansine) (Microtubule inhibitor, HER2-targeted antibody-drug conjugate) |
| Direction: | Resistant |
Evidence:
Source:
Title:
Immune Markers and Tumor-Related Processes Predict Neoadjuvant Therapy Response in the WSG-ADAPT HER2-Positive/Hormone Receptor-Positive Trial in Early Breast Cancer
Published date:
09/29/2021
Excerpt:
In all patients, higher ESR1, MAPT, CXXC5, SLC39A6, and PgR levels were associated with lower pCR, while higher HER2 (also known as ERBB2), TMEM45B, GRB7, and RRM2 levels were associated with higher pCR. A similar tendency was seen for all these genes (except PgR) in the combined T-DM1 arms and the combined ET arms...Higher BAG1 under T-DM1 therapy had favorable impact on pCR, while higher CXXC5 or MAPT essentially reduced the relative efficacy of the T-DM1 therapy arms (vs. the trastuzumab arm).
DOI:
https://doi.org/10.3390/cancers13194884
Trial ID:
